Treatment with the TROP2 ADC sac-TMT led to a 70% objective response rate and progression-free survival was “significantly ...

A Merck & Co. effort to move its PD-1 behemoth Keytruda into early treatment of lung cancer has reached a dead end, along with another bid to expand into a type of early-stage skin cancer. Merck has ...

Add Yahoo as a preferred source to see more of our stories on Google. FILE PHOTO: The Merck logo is seen at a gate to the Merck & Co campus in Rahway, New Jersey, New Jersey (Reuters) -The U.S. Food ...

May 21 (Reuters) - Sichuan Kelun-Biotech Biopharmaceutical said on Thursday its experimental treatment combined with partner ...

Merck (MRK) stock gains as a cancer drug the company develops with Kelun-Biotech bests its Keytruda blockbuster in a ...

Shares of Merck & Co. (MRK) rose 5% on Friday after the pharmaceutical giant reported positive developments across multiple oncology programs, reinforcing investor confidence in its efforts to extend ...

Acceptance based on results from the Phase 3 KEYNOTE-091 trial, the seventh positive pivotal study evaluating a KEYTRUDA-based regimen in earlier stages of cancer The study has dual primary endpoints ...

The Food and Drug Administration approved Keytruda, an immunotherapy agent, for patients with stage 1B, 2 or 3A non-small cell lung cancer. The Food and Drug Administration (FDA) approved Keytruda ...

The Food and Drug Administration approved a Keytruda regimen to be administered before and after surgery for patients with stage 2, 3A or 3B non-small cell lung cancer. The Food and Drug ...

RAHWAY, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the European Commission (EC) has approved KEYTRUDA, Merck’s anti-PD-1 ...

Partners Summit Therapeutics and Akeso are expected to steal the show at the American Society of Clinical Oncology’s annual ...

(Reuters) -The U.S. Food and Drug Administration on Monday approved the expanded use of Merck & Co's blockbuster immunotherapy Keytruda in early-stage patients with non-small cell lung cancer who can ...